Publications and Presentations

Filter By:

Filanesib

05/31/2015

American Society of Clinical Oncology Meeting

A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma

J. A. Zonder, MD, et al.

Encorafenib

05/30/2015

American Society of Clinical Oncology Meeting

A Phase 1/b2 Study of BRAF Inhibitor (BRAFi) Encorafenib (ENCO) Plus MEK Inhibitor (MEKi) Binimetinib (BINI) in Cutaneous Melanoma Patients Naive to BRAFI Treatment

R. Sullivan, et al.

Binimetinib

05/30/2015

American Society of Clinical Oncology Meeting

A phase Ib/II study of MEK162 (binimetinib) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST)

P.Chi, et al.

Binimetinib

05/30/2015

American Society of Clinical Oncology Meeting

A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum

B. J. Monk, MD, et al.

Binimetinib

05/30/2015

American Society of Clinical Oncology Meeting

A Phase 1b dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer

R. N. Grisham, MD, et al.

Encorafenib

04/20/2015

American Association for Cancer Research Annual Meeting

Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models of melanoma identify c-Met as an effective second line combination therapy target

C. Krepler, et al.

Binimetinib

04/19/2015

American Association for Cancer Research Annual Meeting

Evaluation of the nonclinical activity of the MEK inhibitor binimetinib (MEK162) in combination with paclitaxel in PDX models of HGSOC

S. Winski, et al.

Encorafenib

04/18/2015

American Association for Cancer Research Annual Meeting

Phase 1 Study of the Selective BRAFV600 Inhibitor Encorafenib (LGX818) Combined With Cetuximab and With or Without the α-specific PI3K Inhibitor Alpelisib (BYL719) in Patients With Advanced BRAF-mutant Colorectal Cancer

J. Schellens, M.D., et al.

ARRY-614

12/08/2014

American Society of Hematology Annual Meeting

Efficacy of Dual Inhibition of p38 Mitogen Activated Protein Kinase (MAPK) and Tie-2 Kinase in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

L.S. Bachegowda MD MRCP, et al.

ARRY-614

12/05/2014

Clinical Cancer Research

A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

G. Garcia-Manero, et al.